Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9323MR)

This product GTTS-WQ9323MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9323MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2113MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ901MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ12750MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ11750MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ9050MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ8566MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ9338MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11480MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEHD7945A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.